#healthcare #Norway #Oslo #Navamedic ASA #dne pharma AS

Navamedic ASA Expands Its Portfolio Through Acquisition

On June 23, 2025, Navamedic ASA, a well-regarded provider of healthcare products, made a significant announcement regarding its strategic growth initiative. The company, recognized under the OSE ticker "NAVA" and headquartered in Oslo, Norway, revealed its plan to acquire the business of dne pharma AS. This asset purchase agreement marks a pivotal moment for Navamedic as it seeks to solidify its presence in the Nordic and Baltic healthcare markets.

Overview of the Acquisition

Navamedic ASA's acquisition of dne pharma AS is set to enhance its capabilities in delivering high-quality pharmaceuticals to hospitals and pharmacies. The acquisition aligns with Navamedic’s mission to meet specific medical needs while expanding its product offerings. To engage stakeholders further, Navamedic hosted two online presentations on June 24, led by CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand.

The presentations, conducted in Norwegian at noon and in English an hour later, aimed to provide detailed insights into the acquisition process. Interested parties were invited to attend the webcasts by registering via email.

Strategic Importance of the Acquisition

This acquisition is significant not only for its immediate impact on Navamedic's product range but also for its long-term strategic direction. By integrating dne pharma's existing operations and expertise, Navamedic will enhance its market access platform and strengthen its position as a trusted supplier of healthcare products across the Nordic and Baltic regions, as well as in Greece.

Furthermore, this move highlights Navamedic's commitment to addressing the evolving needs of patients and healthcare providers. The expanded portfolio is expected to improve accessibility to essential medications and treatment options, reinforcing the company's dedication to healthcare excellence.

Leadership Insight

CEO Kathrine Gamborg Andreassen emphasized the importance of this acquisition during the presentation, stating that it creates new opportunities for growth and innovation within Navamedic. The integration of dne pharma’s capabilities is seen as a strategic leap that will allow Navamedic to better navigate the complexities of the healthcare landscape, providing enhanced solutions tailored to the needs of its clients.

Simultaneously, CFO Lars Hjarrand noted the financial implications of this acquisition, ensuring stakeholders that the company is on a path of sustainable growth while remaining responsible in its financial commitments during the integration phase.

About Navamedic ASA

Navamedic is known for its robust healthcare product offerings tailored to the needs of hospitals and pharmacies. The company's dedicated approach and commitment to healthcare quality sets it apart in a competitive market. Currently, Navamedic operates across all Nordic countries, the Baltics, and Benelux, with plans to further expand its footprint.

As part of its continued commitment to transparency and stakeholder engagement, Navamedic invites interested participants and analysts to review the presentation materials, which are made available for download post-presentation. This level of engagement ensures that potential investors and healthcare professionals remain informed about the company's growth trajectory and commitment to enhanced healthcare delivery.

In conclusion, Navamedic ASA’s acquisition of dne pharma AS not only represents a strategic enhancement of its service and product offerings but also a reaffirmation of its commitment to fostering innovation and excellence in healthcare. With a focus on addressing specific medical needs, Navamedic is well-positioned to navigate the challenges and opportunities that lie ahead in the evolving healthcare market.